Inflammation and arthritis: perspectives of the glycobiologist

被引:5
作者
Brockhausen, Inka [1 ]
Anastassiades, Tassos P. [1 ,2 ]
机构
[1] Queens Univ, Dept Med, Dept Biochem, Div Rheumatol, Kingston, ON K7L 3N6, Canada
[2] Queens Univ, Osteoporosis Clin, Kingston, ON, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
advanced glycation end product; arthritis; bone; cartilage; collagen; glucosamine; glycoprotein; glycosylation; inflammation;
D O I
10.1586/1744666X.4.2.173
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
This review focuses on the role of glycosylation during the development of joint inflammation and degeneration. Although glycoproteins and glycan-binding proteins have essential functions in bone and cartilage, and in the inflammatory process, their exact roles are still uncertain due to the vast complexity of carbohydrate structures. Glycosylated epitopes have been shown to play a role in the induction of arthritis in animal models. Currently available drugs are aimed at the protection of cartilage and bone structures but new developments in this area should take into account the tight and specific interactions between bone and cartilage. It is anticipated that new agents will help to remodel damaged joints, based on knowledge of cartilage and bone turnover and on the exact role of glycosylated molecules and cell surface receptor glycoproteins in these processes. Highly sensitive imaging techniques and well-characterized in vivo models will accelerate this development.
引用
收藏
页码:173 / 191
页数:19
相关论文
共 153 条
[1]
Glycan modification of the tumor antigen gp100 targets DC-SIGN to enhance dendritic cell induced antigen presentation to T cells [J].
Aanoudse, Corlien A. ;
Bax, Marieke ;
Sanchez-Hernandez, Marta ;
Garcia-Vallejo, Juan J. ;
van Kooyk, Yvette .
INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (04) :839-846
[2]
Recognition of tumor glycans by antigen-presenting cells [J].
Aarnoudse, CA ;
Vallejo, JJG ;
Saeland, E ;
van Kooyk, Y .
CURRENT OPINION IN IMMUNOLOGY, 2006, 18 (01) :105-111
[3]
Alavi A, 2005, ADV EXP MED BIOL, V564, P129
[4]
Alavi A, 2004, J RHEUMATOL, V31, P1513
[5]
Anastassiades T, 2005, J RHEUMATOL, V32, P578
[6]
Impaired selectin-ligand biosynthesis and reduced inflammatory responses in β-1,4-galactosyltransferdse-I-deficient mice [J].
Asano, M ;
Nakae, S ;
Kotani, N ;
Shirafuji, N ;
Nambu, A ;
Hashimoto, N ;
Kawashima, H ;
Hirose, M ;
Miyasaka, M ;
Takasaki, S ;
Iwakura, Y .
BLOOD, 2003, 102 (05) :1678-1685
[7]
Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis [J].
Bäcklund, J ;
Carlsen, S ;
Höger, T ;
Holm, B ;
Fugger, L ;
Kihlberg, J ;
Burkhardt, H ;
Holmdahl, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (15) :9960-9965
[8]
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee - Results of the two-year multinational knee osteoarthritis structural arthritis study [J].
Bingham, Clifton O., III ;
Buckland-Wright, J. Chris ;
Garnero, Patrick ;
Cohen, Stanley B. ;
DougadoS, Maxime ;
Adarni, Silvano ;
Clauw, Daniel J. ;
Spector, Timothy D. ;
Pelletier, Jean-Pierre ;
Raynauld, Jean-Pierre ;
Strand, Vibeke ;
Simon, Lee S. ;
Meyer, Joan M. ;
Cline, Gary A. ;
Beary, John F. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (11) :3494-3507
[9]
Pharmacological treatment of ankylosing spondylitis - A systematic review [J].
Boulos, P ;
Dougados, M ;
MacLeod, SM ;
Hunsche, E .
DRUGS, 2005, 65 (15) :2111-2127
[10]
Biology of RANK, RANKL, and osteoprotegerin [J].
Boyce, Brendan F. ;
Xing, Lianping .
ARTHRITIS RESEARCH & THERAPY, 2007, 9 (Suppl 1)